Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a strong-buy rating to a buy rating in a research report report published on Wednesday morning.

Other research analysts have also issued research reports about the stock. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a report on Wednesday. UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average target price of $20.88.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $21.20 on Wednesday. The company has a market cap of $24.02 billion, a price-to-earnings ratio of -24.94, a price-to-earnings-growth ratio of 0.99 and a beta of 0.79. Teva Pharmaceutical Industries has a 12 month low of $10.13 and a 12 month high of $21.98. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The stock’s 50-day moving average is $17.61 and its 200-day moving average is $17.45.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.55% of the stock is currently owned by corporate insiders.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors have recently added to or reduced their stakes in TEVA. UMB Bank n.a. increased its position in shares of Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after purchasing an additional 2,067 shares during the last quarter. Smithfield Trust Co grew its stake in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries in the third quarter valued at about $50,000. Claro Advisors LLC acquired a new stake in Teva Pharmaceutical Industries during the third quarter valued at approximately $52,000. Finally, Mark Sheptoff Financial Planning LLC acquired a new stake in Teva Pharmaceutical Industries during the second quarter valued at approximately $57,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.